Novo Nordisk has faced a massive selloff in recent months amid disappointing drug trials and U.S. pressure to cut its prices.

In a report released today, James Quigley from Goldman Sachs maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price ...

Unions that provide health benefits to nearly a half-million workers — including many in Ohio — have filed nearly identical ...

UBS analyst Jo Walton maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK750.00. The company’s ...

Detailed price information for GE Healthcare Technologies Inc (GEHC-Q) from The Globe and Mail including charting and trades.

I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

City attorneys allege major Pharmacy Benefit Managers (PBMs) and insulin manufacturers are conspiring to artificially inflate ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

We recently published a list of These 10 Firms Took A Hit on Friday. In this article, we are going to take a look at where ...

The city of Greensboro has joined a national litigation campaign suing the nation's three largest pharmacy benefit managers and three largest insulin manufacturers with the goal of lowering insulin pr ...

According to the American Diabetes Association, approximately 8.4 million people in the United States need insulin to survive ...

Novo Nordisk has made its smart insulin pens available in the UK, giving people treated within the NHS for diabetes access to devices that can monitor and record dosing information for the first time.